ORAL-B
24.8.2022 08:02:04 CEST | Business Wire | Press release
Oral-B, the leading innovator in oral health, announces partnership with the International Association of Disability and Oral Health (iADH) as part of the brand’s drive to make oral care more inclusive, accessible, and positive for people with disabilities, their caregivers, and everyone in between.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005621/en/
Approximately 166 million people in Europe are affected by a disability in some way and recent research reveals that a third (1/3) of those experience gum issues due to struggles with maintaining their oral health1 . Oral-B is on a mission to ensure that everybody has an equitable oral care experience - whether that be at the dentist practice, easily accessible and personalised tips and tricks or with the products that are used at home to maintain oral health.
Benjamin Binot, P&G Europe Oral Care Senior Vice President says: “As the leading innovator in oral health for over 70 years and the #1 dentist recommended brand, we recognise the importance of making oral care accessible to all – and continuously listen to people's experiences with disabilities to understand how we can help them. Through this work, we have learned that oral health care struggles amongst this audience are most common because many haven’t been taught the skills they need to brush their teeth effectively, they experience a sense of inevitability about their teeth deteriorating and may be especially anxious in the dentist’s chair. As a brand, we recognize our responsibility to help ensure that oral care is accessible to all and we are proud to partner with the iADH to work to improve the experience for people living with disabilities.”
The first step of this partnership is to co-create a ‘Positive Practices’ training program designed to train and educate dental practices on how to become more confident and inclusive when it comes to their patients.
Alison Dougall, iADH President says; “We are delighted to be working alongside Oral-B to address the significant oral health inequalities experienced by people with disabilities in Europe, through innovation, education, research and advocacy. By working together, we aim to make a positive difference to the oral care experience for people living with visible and nonvisible disabilities.
iADH exists to improve desired oral health outcomes for people with disabilities and Oral-B exists to create the best oral care outcomes by providing the most rewarding and enjoyable oral care experiences for everyone, everyday – given our shared values, it felt like a very natural fit when Oral-B approached us to come together in partnership”
The brand will also be present at this year’s Biennial iADH Congress 2022 in Paris to learn from the global members, who will be sharing their knowledge and experience to improve oral health outcomes for people with disabilities in a KOL workshop hosted by Oral-B. The findings gathered from the workshop will help to inform Positive Practices and ensure that the training programme is underpinned by insight to deliver the best outcome for change.
-ENDS-
About Oral-B
Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.
About The iADH (International Association of Disability and Oral Health)
The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability
1 The Oral Health & Disability European Study, March 2022, Oral-B
For more information, please visit: https://www.oralb.co.uk/en-gb
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005621/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
